

**Leroy A. Richardson,**  
Chief, Information Collection Review Office,  
Office of Scientific Integrity, Office of the  
Associate Director for Science, Office of the  
Director, Centers for Disease Control and  
Prevention.

[FR Doc. 2016-19460 Filed 8-15-16; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[Docket No. CDC-2016-0083; 60Day-16-  
16AWM]

#### Proposed Data Collection Submitted for Public Comment and Recommendations

**AGENCY:** Centers for Disease Control and  
Prevention, Department of Health and  
Human Services.

**ACTION:** Notice with comment period.

**SUMMARY:** Centers for Disease Control  
and Prevention as part of its continuing  
efforts to reduce public burden and  
maximize the utility of government  
information, invites the general public  
and other Federal agencies to take this  
opportunity to comment on this  
proposed information collections, as  
required by the Paperwork Reduction  
Act of 1995. This notice invites  
comment on the Executive and  
Scientific Resources Office Access  
Management System (EAMTS). EAMTS  
is designed to house all Guest  
Researcher & ORISE program packets,  
Appointment Mechanism Determination  
Forms, and Title 42 Fellowship  
Immigration information in one central  
location on the Human Resources Office  
SharePoint Server.

**DATES:** Written comments must be  
received on or before October 17, 2016.

**ADDRESSES:** You may submit comments,  
identified by Docket No. CDC-2016-  
0083 by any of the following methods:  
Federal eRulemaking Portal:  
*Regulations.gov*. Follow the instructions  
for submitting comments.

*Mail:* Jeffrey M. Zirger, Acting  
Information Collection Review Office,  
Centers for Disease Control and  
Prevention, 1600 Clifton Road NE., MS-  
D74, Atlanta, Georgia 30329.

*Instructions:* All submissions received  
must include the agency name and  
Docket Number. All relevant comments  
received will be posted without change  
to *Regulations.gov*, including any  
personal information provided. For  
access to the docket to read background  
documents or comments received, go to  
*Regulations.gov*.

**Note:** All public comment should be  
submitted through the Federal eRulemaking  
portal (*Regulations.gov*) or by U.S. mail to the  
address listed above.

**FOR FURTHER INFORMATION CONTACT:** To  
request more information on the  
proposed project or to obtain a copy of  
the information collection plan and  
instruments, contact the Information  
Collection Review Office, Centers for  
Disease Control and Prevention, 1600  
Clifton Road NE., MS-D74, Atlanta,  
Georgia 30329; phone: 404-639-7570;  
Email: [omb@cdc.gov](mailto:omb@cdc.gov).

**SUPPLEMENTARY INFORMATION:** Under the  
Paperwork Reduction Act of 1995 (PRA)  
(44 U.S.C. 3501-3520), Federal agencies  
must obtain approval from the Office of  
Management and Budget (OMB) for each  
collection of information they conduct  
or sponsor. In addition, the PRA also  
requires Federal agencies to provide a  
60-day notice in the **Federal Register**  
concerning each proposed collection of  
information, including each new  
proposed collection, each proposed  
extension of existing collection of  
information, and each reinstatement of  
previously approved information  
collection before submitting the  
collection to OMB for approval. To  
comply with this requirement, we are  
publishing this notice of a proposed  
data collection as described below.

Comments are invited on: (a) Whether  
the proposed collection of information  
is necessary for the proper performance  
of the functions of the agency, including  
whether the information shall have  
practical utility; (b) the accuracy of the  
agency's estimate of the burden of the  
proposed collection of information; (c)  
ways to enhance the quality, utility, and  
clarity of the information to be  
collected; (d) ways to minimize the  
burden of the collection of information  
on respondents, including through the  
use of automated collection techniques  
or other forms of information  
technology; and (e) estimates of capital  
or start-up costs and costs of operation,  
maintenance, and purchase of services  
to provide information. Burden means  
the total time, effort, or financial  
resources expended by persons to  
generate, maintain, retain, disclose or  
provide information to or for a Federal  
agency. This includes the time needed  
to review instructions; to develop,  
acquire, install and utilize technology  
and systems for the purpose of  
collecting, validating and verifying  
information, processing and  
maintaining information, and disclosing  
and providing information; to train  
personnel and to be able to respond to  
a collection of information, to search  
data sources, to complete and review

the collection of information; and to  
transmit or otherwise disclose the  
information.

#### Proposed Project

Data Management for Executive and  
Scientific Resources Access  
Management Tracking System—New—  
Executive and Scientific Resource Office  
(ESRO), Centers for Disease Control and  
Prevention (CDC).

#### Background and Brief Description

ESRO seeks to submit and  
information collection request for  
approval of information collections  
through its ESRO Access Management  
Tracking System (EAMTS). This system  
will automate current manual processes  
for programs managed by ESRO. This  
new process will provide users a single,  
integrated location to allow for  
collaboration, faster processing between  
the programs and ESRO and a better  
onboarding experience for potential  
fellows.

EAMTS will support users by  
providing a single, integrated location  
for enterprise content management,  
manage documents and records by using  
workflows an information rights  
management. This business process will  
allow ESRO to design forms that are  
accessible in SharePoint through a Web  
Browser. Team members will be able to  
access critical business information,  
analyze and view data, and publish  
reports to make more informed  
decisions.

EAMTS will allow CIO's to submit  
digital packets including Guest  
Researcher, ORISE, Title 42 Fellowship  
Visa request (portion of CDC 0.1475)  
and Appointment Mechanism  
Determination Request Form (CDC  
0.4601). CIO's can upload supplemental  
documentation as an attachment to each  
application, electronically track and  
monitor status of application, digitally  
sign forms and requests, receive case  
determinations quickly and accurately,  
and track the Visa status of Title 42  
Fellowship requests that require Visa  
assistance from the Human Resources  
Office.

EAMTS is developed in SharePoint  
for CDC's Centers/Institutes/Offices  
(CIO) to submit required information for  
all of Executive and Scientific Resource  
Office's managed programs and for these  
CIO's to effectively and efficiently  
digitally review this information. Data is  
managed and maintained by appropriate  
CIO Staff with ground and form level  
permission.

Permissions to EAMTS are required to  
access the lists, forms, and document  
library. This includes entering data,

clearing/approving forms, processing forms, and acknowledging data entered.

The total estimated annualized burden hours for all respondents are 1,280. There are no costs to respondents

other than their time. CDC will seek a three-year approval from OMB.

#### ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Number of responses per CIO	Average burden per response (in hours)	Total burden (in hours)
Initiator/C//O .....	CDC 0.4601 .....	64	5	1	320
Initiator/C//O .....	CDC 0.410A .....	64	5	1	320
Initiator/C//O .....	CDC 0.410B .....	64	5	1	320
Initiator/C//O .....	Section C of the CDC 0.1475 .....	64	5	1	320
Totals .....	.....	.....	.....	.....	1,280

#### Leroy A. Richardson,

Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention.

[FR Doc. 2016-19461 Filed 8-15-16; 8:45 am]

BILLING CODE 4163-18-P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

##### National Institutes of Health

##### National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Clinical Trial Implementation Cooperative Agreement (U01).

*Date:* September 22, 2016.

*Time:* 10:00 a.m. to 12:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Room 3F100, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

*Contact Person:* Lynn Rust, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room 3G42A, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC 9823,

Bethesda, MD 20892-9823, (240) 669-5069, [lrust@niaid.nih.gov](mailto:lrust@niaid.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: August 10, 2016.

#### Natasha M. Copeland,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2016-19417 Filed 8-15-16; 8:45 am]

BILLING CODE 4140-01-P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

##### National Institutes of Health

##### Prospective Grant of Start-Up Exclusive Evaluation Option License Agreement: Small Molecule Therapeutic Compounds Encompassed Within the Licensed Patent Rights for the Treatment of Thioesterase Deficiency Disorder

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** This notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-Up Exclusive Evaluation Option License Agreement to practice the inventions embodied in the following Patent Applications to Circumvent Pharmaceuticals Inc. (“Circumvent”) located in Pasadena, California, USA:

##### Intellectual Property

United States Provisional Patent Application No. 61/473,692, filed April 8, 2011, titled “Small molecule therapeutic compounds targeting thioesterase deficiency disorders and methods of using the same” [HHS

Reference No. E-157-2011/0-US-01], status: Expired;

International Patent Application No. PCT/US2012/32772 filed April 9, 2012 titled “Small molecule therapeutic compounds targeting thioesterase deficiency disorders and methods of using the same” [HHS Reference No. E-157-2011/0-PCT-02], status: Converted;

European Patent Application No. 12716889.6, filed November 7, 2013, titled “Small molecule therapeutic compounds targeting thioesterase deficiency disorders and methods of using the same” [HHS Reference No. E-157-2011/0-EP-03], status: Pending; and

United States Patent Application No. 14/110,393, filed October 7, 2013, titled “Small molecule therapeutic compounds targeting thioesterase deficiency disorders and methods of using the same” [HHS Reference No. E-157-2011/0-US-04], status: Pending.

The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The territory of the prospective Start-Up Exclusive Evaluation Option License Agreement may be worldwide and the field of use may be limited to: “Small molecule therapeutic compounds encompassed within the Licensed Patent Rights for the treatment of thioesterase deficiency disorders”

Upon the expiration or termination of the Start-up Exclusive Evaluation Option License Agreement, Circumvent will have the exclusive right to execute a Start-Up Exclusive Patent License Agreement which will supersede and replace the Start-up Exclusive Evaluation Option License Agreement, with no greater field of use and territory than granted in the Start-up Exclusive Evaluation Option License Agreement.

**DATES:** Only written comments and/or applications for a license which are received by the NIH Office of